Oppenheimer Initiates Coverage on Eiger BioPharmaceuticals to Outperform

Oppenheimer Initiates Coverage on Eiger BioPharmaceuticals(NASDAQ:EIGR). The shares have been rated Outperform. The rating by Oppenheimer was issued on Jul 5, 2016.

In a different note, Wedbush said it Initiates Coverage on Eiger BioPharmaceuticals, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Outperform’ by the firm. Jefferies said it Initiates Coverage on Eiger BioPharmaceuticals, according to a research note issued on Apr 7, 2016. The shares have been rated ‘Buy’ by the firm.

Eiger BioPharmaceuticals(EIGR) last announced its earnings results on May 16, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-10.42.

Several Insider Transactions has been reported to the SEC. On Jun 22, 2016, James H Welch (CFO) purchased 2,500 shares at $19.80 per share price.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *